Built for teams making longevity biotech decisions
DLT supports pharma, investment and biotech teams with 24/7 market intelligence to capture the $617bn market opportunity.
Already licensed by Top 10 Big Pharmas
FOUR WAYS TO WORK WITH US
01
Big Pharma
02
SME pharma / biotech
03
Investors
04
Custom research
01
BIG PHARMA
Find the next licensing opportunity before it is obvious
DLT helps pharma and corporate development teams identify companies, assets and mechanisms with investment, licensing, licensing or acquisition potential.
A TYPICAL ASK
Which Phase 2 senolytic studies align with our cardiovascular and neurodegeneration programs?
USE DLT TO
Screen companies by mechanism, modality and clinical stage
Identify repurposing and indication-expansion opportunities
Track pre-clinical and clinical stage assets for indication expansion
Monitor competitors, partnerships and clinical progress
Build target lists for licensing and M&A then run comparisons
02
SME PHARMA / BIOTECH
Benchmark and sharpen your strategy
DLT helps biotech and small-cap pharma leadership teams understand competitors, investors, partners and positioning across the longevity biotech landscape.
A TYPICAL ASK
Who else is working on our clinical targets, how far ahead are they, and what does their capitalization look like?
USE DLT TO
Benchmark direct and adjacent competitors
Track all players in your clinical lane
Support fundraising and board materials
Monitor out-licensing and in-licensing opportunities
Understand market movement around M&A then run comparisons
03
INVESTORS
We work alongside investors on deals, not seats
We are not selling platform licences to funds. We use DLT to source, screen and pressure-test opportunities with investors who are active in longevity biotech, and we work with them deal by deal.
WHERE WE ADD VALUE
Screened deal flow drawn from the full company dataset
Second-opinion diligence on a company, asset or mechanism
Landscape work behind a thesis before capital is committed
Introductions across the Longevity.Technology’s investor network
Ongoing signal monitoring on portfolio companies and competitors
04
CUSTOM RESEARCH
When you want a full report not a license
Our research team builds bespoke reports on top of the DLT dataset for questions that need written analysis, primary interviews or a specific commercial framing.
A TYPICAL ASK
Map every company working on a mechanism, rank them for partnering fit, and set out what our board needs to decide.
WHAT WE PRODUCE
Market and competitive landscape reports
Partnering and acquisition target assessments
Due diligence packs on named companies or assets
Mechanism and indication deep dives
Board and investment committee briefings
A WORKED EXAMPLE
AI co-pilot enabled workflows
The same four steps apply whether the output is a licensing shortlist, a partnering brief or a competitor update.
STEP 1
Frame the field
Filter to the mechanism and clinical stage that matter, and see every aligned company in the dataset.
STEP 2
Read the evidence
Open the shortlist and check assets, trial history, patents, and parnerships in each profile.
STEP 3
Put it under watch
Save the companies to your watchlist so trial, financing and partnership moves arrive in your daily email briefing.
STEP 4
Hand it over
At any time, ask the DLT chatbot to run full reports on any company benchmarked to yours or your investments.
WHAT IT REPLACES
The work that usually eats the week
BEFORE
WITH DLT
BEFORE
WITH DLT
BEFORE
WITH DLT
Bring one live question to a 30-minute call
We run the call against the live dataset. Tell us the mechanism, indication or competitor set you are working on and we will show you what DLT holds on it.